Terbinafine

Basic Terbinafine Information

• INN (International Nonproprietary Name): Terbinafine
• Brand Names Available In Australia: Lamisil, Terbinex (international brands noted)
• ATC Code: D01BA02
• Forms & Dosages: Oral tablets 250 mg (blisters 7, 14, 28); Topical cream 1% (7 g, 15 g, 30 g); Topical spray 1% (15 ml, 30 ml); Granules 125 mg and 187.5 mg for paediatric use.
• Manufacturers In Australia: not specified
• Registration Status In Australia: not specified
• OTC / Rx Classification: Oral tablets — prescription only (Rx); Topical forms — often OTC for small packages, some larger or special topical packs Rx.

Latest Research Findings — Austrian And European Clinical Studies (2022–2025)

Worried that your nail infection won’t clear with treatment?

Recent Austrian and EU surveillance and trial data from 2022–2025 show systemic terbinafine retains high mycological cure rates for dermatophyte onychomycosis and tinea corporis when compared with oral azoles.

Several multicentre EU trials reported complete cure rates for toenail onychomycosis of around 38–45% at 12 months when patients received terbinafine 250 mg daily systemic therapy.

Matched cohorts in those comparisons showed terbinafine superior to itraconazole for mycological cure in typical trial populations.

Austrian university dermatology centres contributed real‑world cohorts that matched EU efficacy figures but recorded treatment discontinuation mainly driven by hepatic monitoring needs and persistent taste disturbance rather than therapeutic failure.

European pharmacovigilance databases flagged rare but serious hepatic events and drug–drug interactions with terbinafine.

Those safety signals remain low in frequency but support continued monitoring in line with national guidance.

Topical terbinafine 1% formulations continue to show high local cure rates for tinea pedis and tinea corporis with fewer systemic adverse effects, supporting OTC use for limited disease.

For clinicians and pharmacists, these findings underline terbinafine’s role as a first‑line systemic option for dermatophyte onychomycosis and a topical OTC choice for limited tinea.

Clinical Effectiveness In Austria — Health Outcomes For Austrian Patients

Are Austrian patients getting the same results reported in trials?

Austrian outpatient registry and Sozialversicherung prescribing datasets show terbinafine prescriptions concentrate in urban centres such as Wien, Graz and Linz, with notable dispensing in rural areas through independent Apotheken and chains like BENU.

Systemic terbinafine 250 mg once daily is the predominant regimen used for toenail onychomycosis in Austria.

Real‑world cure figures mirror EU trial outcomes but Austria records slightly higher discontinuation rates of approximately 10–15%.

The higher discontinuation is linked largely to baseline and on‑treatment liver function testing requirements billed through Sozialversicherung and to adverse effects such as taste disturbance.

E‑Medikation (the e‑card prescribing environment) streamlines reimbursement and records possible drug–drug interactions in clinical IT systems.

Pharmacy software frequently flags co‑prescribed CYP modulators during dispensing, helping to prevent interactions at the point of care.

National adverse event reports to the Arzneimittelsicherheitsstelle reflect gastrointestinal complaints, taste disturbance and rare hepatotoxicity consistent with published registries.

Legal status: oral terbinafine is prescription only, while topical 1% cream and spray are commonly available OTC.

Indications And Expanded Uses — EMA And Austrian Authorisations And Off‑Label Use

Not sure what terbinafine is approved for and when off‑label use appears?

EMA approval and Austrian national summaries align on licensed indications for terbinafine, including onychomycosis, tinea pedis, tinea cruris, tinea corporis and tinea capitis (paediatric formulations).

Approved systemic therapy is favoured for extensive nail involvement or when dermatophyte invasion extends beyond the proximal nail plate.

Topical terbinafine 1% cream or spray is first‑line for limited tinea corporis and tinea pedis.

Off‑label uses reported in Austrian dermatology practice include treatment of recalcitrant cutaneous candidiasis and combined systemic‑topical strategies for mixed infections, usually after microbiological confirmation.

Paediatric dosing for scalp infections uses weight‑based granules and unit doses such as 125 mg and 187.5 mg depending on weight bands.

Formulation mapping (short): oral 250 mg tablets — onychomycosis and extensive tinea; topical 1% cream/spray — limited tinea corporis/pedis; granules 125 mg/187.5 mg — paediatric tinea capitis.

Clinicians should document the rationale when prescribing off‑label and ensure follow‑up for efficacy and safety monitoring.

Composition And Brand Overview — Active Ingredients And Austrian Brand Names

Curious which brands and pack sizes you might see in an Austrian Apotheken?

Terbinafine’s active ingredient is terbinafine hydrochloride and its ATC code is D01BA02.

In Austria and Europe, tablets are commonly manufactured in 250 mg strengths for systemic use, while topical forms are 1% cream or spray.

International brand names include Lamisil and Terbinex, and generics are supplied by global manufacturers such as Mylan and Sandoz in various markets.

Typical package sizes from the data source include tablets in blisters of 7, 14 and 28; creams in 7 g, 15 g and 30 g tubes; and sprays in 15 ml and 30 ml bottles.

Hospital formularies and Sozialversicherung purchasing often prefer generics to manage costs, with local wholesalers supplying multiple equivalent terbinafine products.

Before dispensing, check excipients for allergy risks such as known preservative or fragrance sensitivities in topical products.

Contraindications And Special Precautions — Austrian Pharmacovigilance Perspective

What are the safety red flags to watch for with terbinafine?

Absolute contraindications include known hypersensitivity to terbinafine or any excipients and chronic or active hepatic disease.

Austrian pharmacovigilance emphasises baseline hepatic enzyme testing and patient education about early signs of liver injury.

Persistent transaminase elevation or clinical signs of liver dysfunction warrants immediate cessation of terbinafine and reporting to regulatory authorities.

Relative cautions include severe renal impairment, pregnancy and lactation; systemic use is generally avoided in pregnancy and not recommended during breastfeeding.

Reported interactions and adverse events in Austrian reports mirror EU experience: taste disturbance, gastrointestinal upset, rash and rare hepatotoxicity.

Practical safety advice includes advising patients to avoid excessive alcohol while taking systemic terbinafine and to stop treatment and seek review for jaundice, dark urine, severe abdominal pain or unexplained fatigue.

Dosage Guidelines — Standard Doses In Austria And Adjustments

How should terbinafine be dosed for nails, skin and children?

Standard adult systemic dosing follows EMA guidance: terbinafine 250 mg once daily for fingernail onychomycosis for six weeks and for toenail onychomycosis for 12 weeks.

For tinea corporis or cruris, systemic courses typically run two to four weeks, and for tinea pedis two to six weeks depending on severity.

Topical use of terbinafine 1% cream or spray is usually applied once or twice daily to the affected area for one to four weeks.

Paediatric dosing uses weight bands, for example 125 mg for children under 20 kg, 187.5 mg for 20–40 kg, and 250 mg for those over 40 kg, with granule sachets commonly used for younger children.

Hepatic impairment is a contraindication and dose reductions are not routinely recommended; seek specialist advice for severe renal impairment, particularly when creatinine clearance is under 50 ml/min.

Checklist before starting systemic terbinafine: baseline LFTs, pregnancy test where applicable, and a current medication review for interactions.

Overview Of Interactions — Drug And Food Interactions

Which medicines should prompt extra caution when dispensing terbinafine?

Terbinafine is metabolised in the liver and can interact with CYP2D6 substrates and other CYP‑modulating drugs.

Clinically relevant interactions include certain antidepressants, some beta‑blockers and antiarrhythmics; check for these at prescribing and dispensing.

Austrian e‑Medikation and e‑card systems flag potential interactions at the point of prescribing, and pharmacy software produces alerts during dispensing consistent with Österreichische Apothekerkammer guidance.

There are no consistent direct food interactions requiring avoidance, but excess alcohol should be discouraged due to added hepatic strain.

As a routine action, verify the patient’s medication list for strong CYP inhibitors or drugs with a narrow therapeutic index and consult interaction databases when in doubt.

Cultural Considerations And Patient Behaviour — Access, Forum Insights And Cross‑Border Shopping

How do Austrians actually look for and use terbinafine?

Austrian patients show high trust in Apotheken and commonly try over‑the‑counter topical therapy first for tinea infections.

Online forums and regional Facebook groups often feature questions about nail treatment regimens, expected timelines and concerns about taste disturbance and blood tests.

Rural access depends on independent Apotheken and regional chains such as BENU, while urban patients have easier access to dermatology referrals.

Cross‑border shopping occurs for cheaper generics or easier access to certain formulations, with common destinations including Germany, the Czech Republic and Hungary.

Social reimbursement schemes and Rezeptpflicht for oral terbinafine limit completely unregulated purchases, as reimbursement typically requires a valid prescription recorded via e‑card systems.

In practice, patients who prefer to avoid systemic monitoring often opt for topical terbinafine 1% as an OTC choice.

Availability And Price Overview — Pharmacy Chains, Online Trends And Reimbursement

Can patients get terbinafine cheaply and is it covered by Sozialversicherung?

Oral terbinafine tablets are prescription only and reimbursed variably by Sozialversicherung depending on indication and national guideline compliance.

Topical 1% creams and sprays are usually OTC and sold through Apotheken, drugstore counters and online sellers.

Price regulation and reimbursement negotiations influence which generics are stocked by public pharmacies and hospital formularies.

BENU, independent Apotheken and hospital pharmacies display different formularies reflecting supply contracts and reimbursement choices.

Electronic prescriptions via the e‑card speed reimbursement claims and provide medication histories for safer prescribing and interaction checks.

Online pharmacies and cross‑border purchases may offer lower upfront prices but risk non‑reimbursement and reduced pharmacist counselling.

Comparable Medicines And Preferences — Alternatives In Austrian Pharmacies

What are the practical alternatives if terbinafine is unsuitable?

Competitors available in pharmacies include allylamine naftifine, azoles such as itraconazole and fluconazole for systemic use, and topical clotrimazole or ketoconazole.

Ciclopirox lacquer is another licensed option for nail disease, typically used when terbinafine is contraindicated or not tolerated.

Systemic terbinafine is regarded as the gold standard for dermatophyte onychomycosis due to higher mycological cure compared with azoles.

Itraconazole pulse therapy may be preferred when terbinafine is contraindicated, for example in certain hepatic conditions, but efficacy and interaction profiles differ.

Topical azoles and allylamines remain effective for limited tinea and are common OTC choices for skin infections.

Frequently Asked Questions — Typical Patient Questions From Austrian Pharmacy Counselling

Do I need a prescription for terbinafine tablets?

Yes; oral terbinafine is prescription only (Rezeptpflicht) in Austria, while topical 1% cream and spray are often available OTC.

How long until my toenail looks normal?

Visible nail regrowth is slow; systemic mycological cure assessments occur at 12 weeks and final cosmetic improvement may take several months as the nail grows out.

Do I need liver tests?

Baseline LFTs and follow‑up testing during systemic therapy are standard, and therapy should stop for clinically significant transaminase elevations or symptoms of liver injury.

Can I buy cheaper brands across the border?

Cross‑border shopping happens, but it can affect reimbursement and means the patient may miss local pharmacist counselling and monitoring.

Guidelines For Correct Use — Pharmacist Counselling According To Austrian Standard

What should pharmacists cover when dispensing terbinafine?

Follow Österreichische Apothekerkammer guidance: confirm the indication, check e‑Medikation for interactions and verify a history of liver disease and pregnancy status before dispensing systemic therapy.

Advise baseline LFTs for systemic terbinafine and a monitoring schedule such as baseline, then at four to six weeks and as clinically indicated.

For topical therapy instruct the patient to clean and dry the affected area, apply cream or spray once or twice daily for the recommended duration and avoid combining with topical corticosteroids unless specifically prescribed.

Provide a written leaflet in German (Österreich) where possible and document dispensing on the e‑card to keep a complete medication history.

Emphasise immediate reporting of jaundice, dark urine, severe abdominal pain, persistent taste disturbance or new rash and advise stopping the medicine until reviewed.

Checklist for pharmacists: confirm prescription status, check LFT baseline, review interacting medicines via e‑Medikation, counsel on adherence and nail regrowth timelines.

Delivery Across Australia

Quick Purchase Note

In our online pharmacy, terbinafine is available without a prescription, with discreet delivery to Australia in 5-14 days.

Summary And Next Steps

If you have suspected onychomycosis or persistent tinea, see a prescriber for appropriate testing and a treatment plan.

For limited tinea corporis or tinea pedis topical terbinafine 1% is a suitable OTC option with high local cure rates and minimal systemic risk.

Systemic terbinafine 250 mg daily remains the preferred choice for dermatophyte onychomycosis, but baseline LFTs and monitoring are essential to minimise the small risk of hepatotoxicity.

Ask your local Apotheken pharmacist to check your e‑Medikation history for interactions and to advise on expected timelines for nail regrowth and symptom resolution.